JP2016190816A - External composition - Google Patents
External composition Download PDFInfo
- Publication number
- JP2016190816A JP2016190816A JP2015072191A JP2015072191A JP2016190816A JP 2016190816 A JP2016190816 A JP 2016190816A JP 2015072191 A JP2015072191 A JP 2015072191A JP 2015072191 A JP2015072191 A JP 2015072191A JP 2016190816 A JP2016190816 A JP 2016190816A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- ceramides
- oil
- ceramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 229940106189 ceramide Drugs 0.000 claims abstract description 48
- 150000001783 ceramides Chemical class 0.000 claims abstract description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 27
- 229930195729 fatty acid Natural products 0.000 claims abstract description 27
- 239000000194 fatty acid Substances 0.000 claims abstract description 27
- -1 fatty acid ester Chemical class 0.000 claims abstract description 27
- 239000004375 Dextrin Substances 0.000 claims abstract description 25
- 229920001353 Dextrin Polymers 0.000 claims abstract description 25
- 235000019425 dextrin Nutrition 0.000 claims abstract description 25
- 239000010685 fatty oil Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 14
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 6
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- 229940071085 lauroyl glutamate Drugs 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract description 13
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract description 13
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract description 13
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract description 13
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 238000009472 formulation Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000007711 solidification Methods 0.000 description 6
- 230000008023 solidification Effects 0.000 description 6
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 4
- 229940048864 ceramide 1 Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- KZTJQXAANJHSCE-OIDHKYIRSA-N N-octodecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC KZTJQXAANJHSCE-OIDHKYIRSA-N 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 229940099417 ceramide 2 Drugs 0.000 description 3
- 229940044176 ceramide 3 Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- 235000019487 Hazelnut oil Nutrition 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- VJZWIFWPGRIJSN-XRHABHTOSA-N dilinoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O VJZWIFWPGRIJSN-XRHABHTOSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000010468 hazelnut oil Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WAYLDHLWVYQNSQ-KEFDUYNTSA-N N-2-hydroxylignoceroylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC WAYLDHLWVYQNSQ-KEFDUYNTSA-N 0.000 description 1
- IEZRNEGTKRQRFV-LFBNJJMOSA-N N-octadecanoyl-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC IEZRNEGTKRQRFV-LFBNJJMOSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000010394 Solidago odora Nutrition 0.000 description 1
- ZGBFGAHZKZQSLG-UMCOJZBLSA-N [30-oxo-30-[[(e,2s,3r,6r)-1,3,6-trihydroxyoctadec-4-en-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCC[C@@H](O)\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC ZGBFGAHZKZQSLG-UMCOJZBLSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、セラミド類を高濃度で含有する外用組成物、とくに液状または半固形状の外用組成物に関する。 The present invention relates to an external composition containing ceramides at a high concentration, and particularly to a liquid or semi-solid external composition.
セラミド類は、人の皮膚（角層）に存在する細胞間脂質であって、加齢等により角層内のセラミドは減少していくことが知られている。それに伴い皮膚は乾燥して皺などを生じ、またバリア機能の低下によってアレルゲン等の侵入を招き、炎症やかゆみを生じることになる。このような症状に対して、セラミド類を外用することが有効であって、その際セラミド類を溶解状態にすることにより対象部位への浸透を図ることができる。また、濃度依存性があるためできるだけ高濃度で含有させ、浸透力の観点から製剤の性状は液状から半固形状であることが好ましい。 Ceramides are intercellular lipids present in human skin (stratum corneum), and it is known that ceramide in the stratum corneum decreases with aging and the like. Along with this, the skin is dried to cause wrinkles and the like, and due to the lowered barrier function, allergens and the like are invaded, causing inflammation and itching. For such a symptom, it is effective to apply ceramides externally, and in that case, penetration into the target site can be achieved by bringing the ceramides into a dissolved state. Moreover, since it has concentration dependency, it is preferably contained at a concentration as high as possible, and from the viewpoint of osmotic power, the properties of the preparation are preferably liquid to semi-solid.
しかしながら、セラミド類は水にも油にも溶解し難い成分であって、低濃度であっても溶解状態にすることが難しい成分である。セラミド類の溶解性を向上させる方法として、種々の技術が提案されているが、安全性に欠ける等の問題があり、更なる改良が望まれている。また、セラミド類を高濃度で配合すると、製剤が固形化する、析出する等の傾向が見られ、液状〜半固形の性状にとどめ、透明で、使用に耐えうる性状に保つことは非常に困難であった。また、一時的に高濃度で溶解できたとしても、経時的にセラミド類が析出したり、固形化することもあり、安定性に劣るものであった。 However, ceramides are components that are difficult to dissolve in water and oil, and are difficult to be dissolved even at low concentrations. Various techniques have been proposed as methods for improving the solubility of ceramides, but there are problems such as lack of safety, and further improvements are desired. In addition, when ceramides are blended at a high concentration, the formulation tends to solidify and precipitate, and it is very difficult to keep it in a liquid to semi-solid state, transparent and endurable to use. Met. Moreover, even if it could be dissolved at a high concentration temporarily, ceramides may precipitate over time or solidify, and the stability was poor.
たとえば特許文献１では、脂肪酸トリグリセリドおよびフィトステロール誘導体を含む組成物が提案され、特許文献２では、ポリグリセリン脂肪酸エステルおよび脂肪酸モノグリセリドを含む組成物が提案されている。しかしながら、これらの文献で具体的に開示されている組成物ではセラミド類の濃度は低いものであった。 For example, Patent Document 1 proposes a composition containing a fatty acid triglyceride and a phytosterol derivative, and Patent Document 2 proposes a composition containing a polyglycerol fatty acid ester and a fatty acid monoglyceride. However, in the compositions specifically disclosed in these documents, the concentration of ceramides was low.
本発明は、セラミド類を高濃度で含有するにもかかわらず、均一で安定性の高い外用組成物を提供することを目的とする。 An object of the present invention is to provide a uniform and highly stable composition for external use despite containing a high concentration of ceramides.
本発明者らは、セラミド類の高濃度化について鋭意研究したところ、（Ａ）セラミド類を２．５〜６重量％と高濃度で含有するにも関わらず、（Ｂ）フィトステロール誘導体を１５〜３０重量％、（Ｃ）脂肪油、（Ｄ）デキストリン脂肪酸エステルを配合することにより、外用組成物が固形となることなく、液状〜半固形状の外用組成物とすることができることを見出した。さらに、（Ｅ）高級アルコールを配合すると、析出、分離、固形化等を起こさない安定性に優れる透明な組成物となることも見出し、本発明を完成した。 The inventors of the present invention have made extensive studies on increasing the concentration of ceramides, and, despite containing (A) ceramides at a high concentration of 2.5 to 6% by weight, (B) phytosterol derivatives 15 to 15%. It has been found that by blending 30% by weight, (C) fatty oil and (D) dextrin fatty acid ester, the external composition can be made into a liquid to semi-solid external composition without becoming solid. Furthermore, it has also been found that when (E) a higher alcohol is blended, it becomes a transparent composition excellent in stability without causing precipitation, separation, solidification, etc., and the present invention has been completed.
すなわち、本発明は、（Ａ）セラミド類２．５〜６重量％、（Ｂ）フィトステロール誘導体１５〜３０重量％、（Ｃ）脂肪油、および、（Ｄ）デキストリン脂肪酸エステルを含有する外用組成物に関する。 That is, the present invention provides an external composition comprising (A) ceramides 2.5 to 6% by weight, (B) phytosterol derivative 15 to 30% by weight, (C) fatty oil, and (D) dextrin fatty acid ester. About.
（Ｂ）フィトステロール誘導体が、ダイマージリノール酸（フィトステリル／イソステアリル／セチル／ステアリル／ベヘニル）、ダイマージリノール酸ジ（イソステアリル／フィトステリル）、ラウロイルグルタミン酸ジ（オクチルドデシル／フィトステリル／ベヘニル）、および、ラウロイルグルタミン酸ジ（フィトステリル／オクチルドデシル）からなる群から選ばれる１または２種以上であることが好ましい。 (B) phytosterol derivatives are dimer linoleic acid (phytosteryl / isostearyl / cetyl / stearyl / behenyl), dimer linoleic acid di (isostearyl / phytosteryl), lauroyl glutamate (octyldodecyl / phytosteryl / behenyl), and One or more selected from the group consisting of dilauroyl glutamate (phytosteryl / octyldodecyl) is preferable.
さらに、（Ｅ）高級アルコールを含有することが好ましい。 Furthermore, it is preferable to contain (E) a higher alcohol.
（Ｃ）脂肪油を５８〜７９．９重量％、（Ｄ）デキストリン脂肪酸エステルを０．１〜１重量％、（Ｅ）高級アルコールを２．５〜６重量％含有することが好ましい。 (C) It is preferable to contain 58 to 79.9% by weight of fatty oil, (D) 0.1 to 1% by weight of dextrin fatty acid ester, and (E) 2.5 to 6% by weight of higher alcohol.
前記外用組成物は、液状または半固形状であることが好ましい。 The external composition is preferably liquid or semi-solid.
本発明によれば、（Ｂ）フィトステロール誘導体、（Ｃ）脂肪油、および、（Ｄ）デキストリン脂肪酸エステルを含有するため、（Ａ）セラミド類を高濃度で含有させることができ、また、高濃度で含有するにもかかわらず、均一で安定性の高い外用組成物を提供することができる。 According to the present invention, since (B) a phytosterol derivative, (C) fatty oil, and (D) a dextrin fatty acid ester are contained, (A) ceramides can be contained at a high concentration. In spite of being contained in, it can provide a uniform and highly stable composition for external use.
本発明の外用組成物は、（Ａ）セラミド類２．５〜６重量％、（Ｂ）フィトステロール誘導体１５〜３０重量％、（Ｃ）脂肪油、および、（Ｄ）デキストリン脂肪酸エステルを含有することを特徴とする。 The composition for external use of the present invention contains (A) ceramides 2.5 to 6% by weight, (B) phytosterol derivatives 15 to 30% by weight, (C) fatty oil, and (D) dextrin fatty acid ester. It is characterized by.
（Ａ）セラミド類とは、スフィンゴシンまたはフィトスフィンゴシン等のスフィンゴシンの類似塩基を中心の骨格とし、アミド結合により、ＯＨをもたない脂肪酸、α−ヒドロキシ脂肪酸又はω−ヒドロキシ脂肪酸と結合している化合物である。人の皮膚（角質）に存在する細胞間脂質を構成する成分であって、保湿性向上やバリア機能向上のために外用される。 (A) Ceramides are compounds that have a sphingosine or similar base of sphingosine such as phytosphingosine as a central skeleton, and are bonded to a fatty acid, α-hydroxy fatty acid or ω-hydroxy fatty acid having no OH by an amide bond It is. It is a component that constitutes intercellular lipid present in human skin (keratin), and is used externally for improving moisture retention and improving barrier function.
（Ａ）セラミド類としては、合成型、天然型等の由来を問わないが、天然又は天然型セラミドが望ましい。例えば、セラミド１（セラミドＩ）、セラミド２（セラミドＩＩ）、セラミド３（セラミドＩＩＩ）、セラミド４（セラミドＩＶ）、セラミド５（セラミドＶ）、セラミド６（セラミドＶＩ）等を挙げることができる。これらの中では、抗しわ効果や保湿性等の有効性の点で、セラミド１、セラミド２およびセラミド３が好ましい。これらのセラミド類は、１種単独でも、２種以上を組み合わせて使用することもできる。 (A) The ceramides may be derived from synthetic or natural types, but natural or natural ceramides are preferred. Examples thereof include ceramide 1 (ceramide I), ceramide 2 (ceramide II), ceramide 3 (ceramide III), ceramide 4 (ceramide IV), ceramide 5 (ceramide V), and ceramide 6 (ceramide VI). Among these, ceramide 1, ceramide 2 and ceramide 3 are preferable in terms of effectiveness such as an anti-wrinkle effect and moisture retention. These ceramides can be used alone or in combination of two or more.
（Ａ）セラミド類の含有量は、外用組成物中２．５〜６重量％であるが、２．５〜５重量％が好ましい。２．５重量％未満では、使用者の満足度が充分ではなくなる傾向がなり、６重量％を超えると、液状又は半固形状の組成物とならないことがある。 (A) Although content of ceramides is 2.5 to 6 weight% in an external composition, 2.5 to 5 weight% is preferable. If the amount is less than 2.5% by weight, the user's satisfaction tends to be insufficient. If the amount exceeds 6% by weight, the composition may not be liquid or semi-solid.
（Ｂ）フィトステロール誘導体とは、生体類似成分であり肌荒改善効果が有する。たとえば、ダイマージリノール酸（フィトステリル／イソステアリル／セチル／ステアリル／ベヘニル）、ダイマージリノール酸ジ（イソステアリル／フィトステリル）、ラウロイルグルタミン酸ジ（オクチルドデシル／フィトステリル／ベヘニル）、ラウロイルグルタミン酸ジ（フィトステリル／オクチルドデシル）等が挙げられる。これらの誘導体は、１種単独でも、２種以上を組合せて使用することもできる。 (B) A phytosterol derivative is a biologically similar component and has an effect of improving skin roughness. For example, dimer dilinoleic acid (phytosteryl / isostearyl / cetyl / stearyl / behenyl), dimer dilinoleic acid di (isostearyl / phytosteryl), lauroyl glutamate di (octyldodecyl / phytosteryl / behenyl), lauroyl glutamate di (phytosteryl / octyl) Dodecyl) and the like. These derivatives can be used alone or in combination of two or more.
（Ｂ）フィトステロール誘導体の含有量は、外用組成物中１５〜３０重量％であるが、１５〜２０重量％が好ましい。１５重量％未満では、性状安定性に欠ける組成物となる傾向があり、３０重量％を超えると、液状又は半固形状の組成物とならないことがある。 (B) Although content of a phytosterol derivative is 15-30 weight% in a composition for external use, 15-20 weight% is preferable. If it is less than 15% by weight, it tends to be a composition lacking in property stability, and if it exceeds 30% by weight, it may not be a liquid or semi-solid composition.
また、（Ｂ）フィトステロール誘導体の、（Ａ）セラミド類に対する比率については、前述する（Ａ）セラミド類、（Ｂ）フィトステロール誘導体の含有量の範囲内を充足しうる範囲内であればよいが、具体的には、（Ａ）セラミド類１重量部あたり、（Ｂ）フィトステロール誘導体が２．５〜１２重量部、より好ましくは３〜１２重量部が挙げられる。 Further, the ratio of (B) phytosterol derivative to (A) ceramides may be within a range that can satisfy the range of the content of (A) ceramides and (B) phytosterol derivatives described above, Specifically, (B) phytosterol derivative is 2.5 to 12 parts by weight, more preferably 3 to 12 parts by weight, per 1 part by weight of (A) ceramides.
（Ｃ）脂肪油とは、油脂のうち常温で液状の油である。たとえば、オリーブ油、マカデミアナッツ油、山茶花油、椿油、トウモロコシ油、ごま油、ホホバ油、サフラワー油、ヒマワリ種子油、ヘーゼルナッツ油、ユチャ油等の植物油が挙げられる。中でも、組成物の性状や使用感の点で、オリーブ油、マカデミアナッツ油、ヒマワリ種子油、ヘーゼルナッツ油、ユチャ油などが好ましい。これらの脂肪油は、１種単独でも、２種以上を組み合わせて使用することもできる。 (C) Fat oil is oil that is liquid at room temperature among fats and oils. Examples include vegetable oils such as olive oil, macadamia nut oil, mountain tea flower oil, coconut oil, corn oil, sesame oil, jojoba oil, safflower oil, sunflower seed oil, hazelnut oil, yucha oil and the like. Of these, olive oil, macadamia nut oil, sunflower seed oil, hazelnut oil, yucha oil and the like are preferable from the viewpoint of the properties and feeling of use of the composition. These fatty oils can be used singly or in combination of two or more.
（Ｃ）脂肪油の含有量は、外用組成物中５８〜７９．９重量％が好ましく、６３〜７９．９重量％がより好ましい。５８重量％未満では、液状又は半固形状の組成物とならないことがあり、７９．９重量％を超えると、性状安定性に欠ける組成物となる傾向にある。 (C) 58-79.9 weight% is preferable in an external composition, and, as for content of a fatty oil, 63-79.9 weight% is more preferable. If it is less than 58% by weight, it may not be a liquid or semi-solid composition, and if it exceeds 79.9% by weight, it tends to be a composition lacking in property stability.
また、（Ｃ）脂肪油の、（Ａ）セラミド類に対する比率については、前述する（Ａ）セラミド類、（Ｃ）脂肪油の含有量の範囲内を充足しうる範囲内であればよいが、具体的には、（Ａ）セラミド類１重量部あたり、（Ｃ）脂肪油が９〜３２重量部、より好ましくは１１〜３２重量部が挙げられる。 In addition, the ratio of (C) fatty oil to (A) ceramides may be within a range that can satisfy the range of the content of (A) ceramides and (C) fatty oil described above. Specifically, (C) fatty oil is 9 to 32 parts by weight, more preferably 11 to 32 parts by weight per part by weight of (A) ceramides.
（Ｄ）デキストリン脂肪酸エステルとは、デキストリンと高級脂肪酸のエステルであって、乳化剤としての用途が知られ、液状油に増粘性を付与する機能等を有する。（Ｄ）デキストリン脂肪酸エステルとしては、たとえば、ミリスチン酸デキストリン、パルミチン酸デキストリン、（パルミチン酸／エチルへキサン酸）デキストリン、オクタン酸デキストリンなどが挙げられる。中でも、性状安定性の点で、ミリスチン酸デキストリンが好ましい。これらのデキストリン脂肪酸エステルは、１種単独でも、２種以上を組み合わせて使用することもできる。 (D) Dextrin fatty acid ester is an ester of dextrin and higher fatty acid, and its use as an emulsifier is known and has a function of imparting viscosity to liquid oil. Examples of (D) dextrin fatty acid ester include myristic dextrin, palmitic dextrin, (palmitic acid / ethylhexanoic acid) dextrin, and octanoic acid dextrin. Of these, dextrin myristate is preferable from the viewpoint of property stability. These dextrin fatty acid esters can be used alone or in combination of two or more.
また、（Ｄ）デキストリン脂肪酸エステルの、（Ａ）セラミド類に対する比率については、前述する（Ａ）セラミド類、（Ｄ）デキストリン脂肪酸エステルの含有量の範囲内を充足しうる範囲内であればよいが、具体的には、（Ａ）セラミド類１重量部あたり、（Ｄ）デキストリン脂肪酸エステルが０．０１〜０．４重量部、より好ましくは０．０８〜０．２重量部が挙げられる。 In addition, the ratio of (D) dextrin fatty acid ester to (A) ceramide may be within a range that can satisfy the above-described content ranges of (A) ceramide and (D) dextrin fatty acid ester. However, specifically, (D) dextrin fatty acid ester is 0.01 to 0.4 part by weight, more preferably 0.08 to 0.2 part by weight per part by weight of (A) ceramide.
（Ｄ）デキストリン脂肪酸エステルの含有量は、外用組成物中０．１〜１重量％が好ましく、０．１〜０．５重量％がより好ましい。０．１重量％未満では、性状安定性にかける組成物となり、１重量％を超えると、液状又は半固形状の組成物とならないことがある。 The content of (D) dextrin fatty acid ester is preferably 0.1 to 1% by weight, more preferably 0.1 to 0.5% by weight in the composition for external use. If the amount is less than 0.1% by weight, the composition is subjected to property stability. If the amount exceeds 1% by weight, the composition may not be liquid or semi-solid.
（Ｅ）高級アルコールとは、一般的に炭素数６以上のアルコールであって、本発明の外用組成物に配合することによって、安定性に優れた透明な組成物を得ることができる。常温で液状の性状であるものが望ましい。具体例としては、たとえばイソステアリルアルコール、オレイルアルコール、オクチルドデカノール、ヘキシルデカノール、デシルテトラデカノール等が挙げられる。中でも、組成物の安定性の点で、イソステアリルアルコールが好ましい。これらの高級アルコールは１種単独でも、２種以上を組み合わせて使用することもできる。 (E) The higher alcohol is generally an alcohol having 6 or more carbon atoms, and a transparent composition excellent in stability can be obtained by blending into the external composition of the present invention. What is a liquid property at normal temperature is desirable. Specific examples include isostearyl alcohol, oleyl alcohol, octyldodecanol, hexyldecanol, decyltetradecanol and the like. Among these, isostearyl alcohol is preferable from the viewpoint of the stability of the composition. These higher alcohols can be used alone or in combination of two or more.
（Ｅ）高級アルコールの含有量は、外用組成物中２．５〜６重量％が好ましく、２．５〜５重量％がより好ましい。２．５重量％未満では、性状安定性に欠ける組成物となり、６重量％を超えると、使用感が低下する傾向にある。 (E) The content of the higher alcohol is preferably 2.5 to 6% by weight, more preferably 2.5 to 5% by weight in the composition for external use. If it is less than 2.5% by weight, the composition lacks property stability, and if it exceeds 6% by weight, the feeling of use tends to be lowered.
また、（Ｅ）高級アルコールの、（Ａ）セラミド類に対する比率については、前述する（Ａ）セラミド類、（Ｅ）高級アルコールの含有量の範囲内を充足しうる範囲内であればよいが、具体的には、（Ａ）セラミド類１重量部あたり、（Ｅ）高級アルコールが０．４〜２．４重量部、より好ましくは０．５〜２重量部が挙げられる。 In addition, the ratio of (E) higher alcohol to (A) ceramides may be within a range that can satisfy the above-described content range of (A) ceramides and (E) higher alcohol. Specifically, (A) higher alcohol is 0.4 to 2.4 parts by weight, more preferably 0.5 to 2 parts by weight per part by weight of (A) ceramides.
本発明の外用組成物は、浸透力や塗りやすさ等の点で、液状または半固形状であることが好ましい。液状または半固形状の外用組成物としては、ゲル、クリームなどが挙げられる。また、本発明の外用組成物は、保湿効果が高いため、美容液、抗しわ用液、保湿剤、スキンオイル、ベビーオイル、日焼け用オイル、パック剤、爪用オイルなどの用途に適用することができる。 The composition for external use of the present invention is preferably liquid or semi-solid in terms of penetrating power and ease of application. Examples of the liquid or semisolid external composition include gels and creams. In addition, since the composition for external use of the present invention has a high moisturizing effect, it should be applied to applications such as cosmetic liquids, anti-wrinkle liquids, moisturizers, skin oils, baby oils, tanning oils, packs, and nail oils. Can do.
本発明の外用組成物は、前述する成分以外に、本発明の効果を損なわない範囲で、当該技術分野で通常使用される成分を含有していてもよい。このような成分としては、例えば、防腐剤、殺菌剤、抗菌剤、消炎剤、湿潤剤、賦形剤、香料、清涼化剤、色素、界面活性剤、ｐＨ調整剤等が挙げられる。 The composition for external use of this invention may contain the component normally used in the said technical field in the range which does not impair the effect of this invention other than the component mentioned above. Examples of such components include antiseptics, bactericides, antibacterial agents, anti-inflammatory agents, wetting agents, excipients, fragrances, cooling agents, dyes, surfactants, pH adjusters, and the like.
また本発明の外用組成物には、必要に応じて、本発明の効果を損なわない範囲で、セラミド以外の生理活性成分や薬理活性成分を配合することもできる。このような成分としてば、ビタミン類、アミノ酸やその重合物（ペプチド、蛋白質）、ポリフェノール、植物エキス、ローヤルゼリー、タンパク質、カルニチン、乳酸菌、エラスチン、コラーゲン、ヒアルロン酸などを例示することができる。 Moreover, in the composition for external use of this invention, physiologically active components and pharmacologically active components other than ceramide can also be mix | blended with the external composition of this invention as needed in the range which does not impair the effect of this invention. Examples of such components include vitamins, amino acids and their polymers (peptides, proteins), polyphenols, plant extracts, royal jelly, proteins, carnitine, lactic acid bacteria, elastin, collagen, hyaluronic acid, and the like.
本発明の外用組成物は、前述の各成分を混合することによって作製するが、混合する際に、たとえば８０〜１５０℃に加熱してもよい。 The composition for external use of the present invention is prepared by mixing the above-described components, and may be heated to, for example, 80 to 150 ° C. when mixing.
実施例に基づいて、本発明を具体的に説明するが、本発明はこれらのみに限定されるものではない。 The present invention will be specifically described based on examples, but the present invention is not limited to these examples.
実施例１〜１０及び比較例１〜８
表１に示す含有量の各成分を約１００℃〜１２０℃に加温し、攪拌、混合、冷却することにより外用組成物を作製した。得られた組成物について、製剤の性状を以下に示す基準で評価した。また、さらに２５℃で１週間放置し、分離、析出(透明性）、固化の発生を基準に以下の基準で安定性を評価した。各項目の評価結果を表１に示す。なお、表１の単位は「重量％」である。表１のセラミド２および３については、それぞれ以下の原料を使用した。
セラミド２：Ｎ−ステアロイルジヒドロスフィンゴシン（商品名：ＣＥＲＡＭＩＤＥ ＴＩＣ−００１（高砂香料工業株式会社製））
セラミド３：Ｎ−ステアロイルフィトスフィンゴシン（ＣＥＲＡＭＩＤＥ ＩＩＩ（エボニックジャパン株式会社製））
Examples 1-10 and Comparative Examples 1-8
Each component having a content shown in Table 1 was heated to about 100 ° C. to 120 ° C., and stirred, mixed, and cooled to prepare an external composition. About the obtained composition, the property of a formulation was evaluated on the basis of the following. Further, the sample was allowed to stand at 25 ° C. for 1 week, and the stability was evaluated based on the following criteria based on the occurrence of separation, precipitation (transparency) and solidification. The evaluation results for each item are shown in Table 1. The unit in Table 1 is “% by weight”. For ceramides 2 and 3 in Table 1, the following raw materials were used.
Ceramide 2: N-stearoyl dihydrosphingosine (trade name: CERAMIDE TIC-001 (manufactured by Takasago International Corporation))
Ceramide 3: N-stearoyl phytosphingosine (CERAMIDE III (Evonik Japan Co., Ltd.))
＜製剤の性状＞
○：液状
△：半固形
×：固形
<Properties of formulation>
○: Liquid △: Semi-solid ×: Solid
＜安定性＞
○：分離／析出／固化の発生なし
×：分離／析出／固化のうち１種以上が発生
<Stability>
○: No separation / precipitation / solidification ×: One or more of separation / precipitation / solidification occurred
表１から明らかなように、製剤中にセラミド類を２．５〜６重量％、フィトステロール誘導体を１５〜３０重量％、脂肪油、デキストリン脂肪酸エステルを含有する実施例１〜１０の外用組成物では、液状又は半固形状の組成物となり、さらに高級アルコールを含有するとセラミドの析出や製剤の分離、固化を防ぐことができ、前記性状と透明性を保つことができた。特に、デキストリン脂肪酸エステルの含有量が０．１〜０．５重量％である場合に、液状の組成物となった（実施例１、４、５、７〜１０）。 As is apparent from Table 1, in the preparations for external use of Examples 1 to 10 containing 2.5 to 6% by weight of ceramides, 15 to 30% by weight of phytosterol derivatives, fatty oil and dextrin fatty acid ester in the preparation. When the composition became liquid or semi-solid and further contained higher alcohol, precipitation of ceramide, separation and solidification of the preparation could be prevented, and the properties and transparency could be maintained. In particular, when the content of the dextrin fatty acid ester was 0.1 to 0.5% by weight, a liquid composition was obtained (Examples 1, 4, 5, 7 to 10).
一方、製剤中にセラミドを２．５重量％以上含有する場合に、フィトステロール誘導体が製剤中に１５重量％未満であって、デキストリン脂肪酸エステルを含まない比較例１〜３、６〜８の外用組成物や、デキストリン脂肪酸エステルの代わりに、同様の機能や用途が知られる脂肪酸エステルを含有させた比較例４および５の外用組成物では、液状又は半固形状の組成物とならず、またセラミドの析出や製剤の分離、固化を生じた。 On the other hand, when ceramide is contained in the preparation in an amount of 2.5% by weight or more, the composition for external use of Comparative Examples 1 to 3 and 6 to 8 in which the phytosterol derivative is less than 15% by weight in the preparation and does not contain dextrin fatty acid ester In the composition for external use of Comparative Examples 4 and 5 containing a fatty acid ester having a similar function and use instead of the product or dextrin fatty acid ester, it does not become a liquid or semi-solid composition. Precipitation, separation of the formulation and solidification occurred.
処方例１〜３
表２に、本発明の外用組成物の処方例を示す。なお、表２の単位は「重量％」である。表２のセラミド１については以下の原料を、セラミド２および３については表１と同一の原料をそれぞれ使用した。
セラミド１：Ｎ−（２７−ステアロイルオキシヘプタコサノイル）フィトスフィンゴシン（商品名：ＣＥＲＡＭＩＤＥ Ｉ（エボニックジャパン株式会社製））
Formulation Examples 1-3
Table 2 shows formulation examples of the composition for external use of the present invention. The unit in Table 2 is “% by weight”. The following raw materials were used for ceramide 1 in Table 2, and the same raw materials as in Table 1 were used for ceramides 2 and 3, respectively.
Ceramide 1: N- (27-stearoyloxyheptacosanoyl) phytosphingosine (trade name: CERAMIDE I (Evonik Japan Co., Ltd.))
これらの処方例に示した外用組成物も、同様に良好な安定性を示した。 The compositions for external use shown in these formulation examples also showed good stability.
本発明の外用組成物は、セラミド類を高濃度で含有するにもかかわらず、液状又は半固形状であるため、浸透性に優れ、使用感が良好であり、美容液、抗しわ用液、保湿剤、スキンオイル、ベビーオイル、日焼け用オイル、パック剤、爪用オイルなどの様々な用途に適用することができる。 The composition for external use of the present invention is liquid or semi-solid despite containing a high concentration of ceramides, so it has excellent permeability and good usability, and is a cosmetic liquid, anti-wrinkle liquid, It can be applied to various uses such as moisturizer, skin oil, baby oil, suntan oil, pack agent, nail oil.
Claims (5)
（Ｂ）フィトステロール誘導体１５〜３０重量％、
（Ｃ）脂肪油、および、
（Ｄ）デキストリン脂肪酸エステル
を含有する外用組成物。 (A) Ceramides 2.5 to 6% by weight,
(B) 15-30% by weight of phytosterol derivative,
(C) fatty oil, and
(D) An external composition containing a dextrin fatty acid ester.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015072191A JP6637246B2 (en) | 2015-03-31 | 2015-03-31 | External composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015072191A JP6637246B2 (en) | 2015-03-31 | 2015-03-31 | External composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016190816A true JP2016190816A (en) | 2016-11-10 |
| JP6637246B2 JP6637246B2 (en) | 2020-01-29 |
Family
ID=57245147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015072191A Active JP6637246B2 (en) | 2015-03-31 | 2015-03-31 | External composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6637246B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018221603A1 (en) | 2017-05-30 | 2018-12-06 | 花王株式会社 | Water-in-oil emulsion composition |
| KR20210068692A (en) | 2019-12-02 | 2021-06-10 | 주식회사 위즈켐 | Multilamella emulsion type cosmetic composition |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002138012A (en) * | 2000-10-30 | 2002-05-14 | Kao Corp | Oily solid cosmetic |
| JP2007022997A (en) * | 2005-07-21 | 2007-02-01 | Kao Corp | Emulsified composition |
| JP2007262033A (en) * | 2006-03-30 | 2007-10-11 | Kose Corp | Oleaginous cosmetic |
| JP2008143822A (en) * | 2006-12-08 | 2008-06-26 | Kao Corp | Skin cosmetic |
| JP2008201753A (en) * | 2007-02-22 | 2008-09-04 | Kose Corp | Skin preparation for external use |
| JP2008297301A (en) * | 2007-05-01 | 2008-12-11 | Fancl Corp | Ceramide solution and dermatological preparation for external use |
| JP2010006786A (en) * | 2008-06-30 | 2010-01-14 | Mochida Pharmaceut Co Ltd | Skin care preparation for external use |
| JP2011178693A (en) * | 2010-02-26 | 2011-09-15 | Kose Corp | Beauty method |
| JP2012201663A (en) * | 2011-03-28 | 2012-10-22 | Kose Corp | Ceramide-containing composition |
| JP2013194000A (en) * | 2012-03-21 | 2013-09-30 | Mikimoto Pharmaceut Co Ltd | Water-in-oil or oil-in-water-in-oil emulsion |
| JP2016108243A (en) * | 2014-12-02 | 2016-06-20 | 日本メナード化粧品株式会社 | Emulsion cosmetic |
-
2015
- 2015-03-31 JP JP2015072191A patent/JP6637246B2/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002138012A (en) * | 2000-10-30 | 2002-05-14 | Kao Corp | Oily solid cosmetic |
| JP2007022997A (en) * | 2005-07-21 | 2007-02-01 | Kao Corp | Emulsified composition |
| JP2007262033A (en) * | 2006-03-30 | 2007-10-11 | Kose Corp | Oleaginous cosmetic |
| JP2008143822A (en) * | 2006-12-08 | 2008-06-26 | Kao Corp | Skin cosmetic |
| JP2008201753A (en) * | 2007-02-22 | 2008-09-04 | Kose Corp | Skin preparation for external use |
| JP2008297301A (en) * | 2007-05-01 | 2008-12-11 | Fancl Corp | Ceramide solution and dermatological preparation for external use |
| JP2010006786A (en) * | 2008-06-30 | 2010-01-14 | Mochida Pharmaceut Co Ltd | Skin care preparation for external use |
| JP2011178693A (en) * | 2010-02-26 | 2011-09-15 | Kose Corp | Beauty method |
| JP2012201663A (en) * | 2011-03-28 | 2012-10-22 | Kose Corp | Ceramide-containing composition |
| JP2013194000A (en) * | 2012-03-21 | 2013-09-30 | Mikimoto Pharmaceut Co Ltd | Water-in-oil or oil-in-water-in-oil emulsion |
| JP2016108243A (en) * | 2014-12-02 | 2016-06-20 | 日本メナード化粧品株式会社 | Emulsion cosmetic |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018221603A1 (en) | 2017-05-30 | 2018-12-06 | 花王株式会社 | Water-in-oil emulsion composition |
| KR20210068692A (en) | 2019-12-02 | 2021-06-10 | 주식회사 위즈켐 | Multilamella emulsion type cosmetic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6637246B2 (en) | 2020-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5342736B2 (en) | Oil-in-water emulsion and method for producing the same | |
| JP2014073991A (en) | Emulsion composition | |
| JP3642788B2 (en) | Cosmetic and / or medicinal preparations with improved skin feel | |
| JP6118546B2 (en) | Oil-in-water emulsion composition | |
| JP5944707B2 (en) | Water-in-oil or oil-in-water oil-in-water emulsions | |
| JP6423701B2 (en) | Cosmetics | |
| KR102198554B1 (en) | W/o type emulsion and a premix for producing the same | |
| JP2013001698A (en) | Oily gel cleansing composition | |
| JP6637246B2 (en) | External composition | |
| JP7063265B2 (en) | Creamy composition | |
| JP4832000B2 (en) | Water-in-oil emulsion composition | |
| JP2016190817A (en) | External composition | |
| JP6606833B2 (en) | Ceramides-containing liposome dispersion | |
| JP5306675B2 (en) | Sucrose fatty acid ester and emulsifier for oil-in-water emulsion composition | |
| JP2007126438A (en) | Emulsified skin preparation for external use and method for stabilizing the emulsified skin preparation for external use | |
| JPS61204109A (en) | Emulsion-type composition for external use | |
| JP5923302B2 (en) | Oil-in-water emulsion composition | |
| JP5777859B2 (en) | Emulsified composition | |
| JP5495852B2 (en) | Topical skin preparation | |
| JP5662750B2 (en) | Water-in-oil emulsion composition | |
| JP2020121954A (en) | Multilayered cosmetics | |
| JP7500355B2 (en) | O/W type emulsion composition | |
| JP6886807B2 (en) | Oily stick-like external composition containing high-concentration ceramide | |
| JP6232285B2 (en) | Cosmetics | |
| WO2024134242A1 (en) | Oil-in-water emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180216 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190710 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191021 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191220 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6637246 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |